Protagenic Therapeutics (PTIX) chair purchases 26,291 company shares

Rhea-AI Filing Summary

Protagenic Therapeutics, Inc. executive chair and principal officer Armen Garo purchased 26,291 shares of common stock on July 30, 2026 at $0.1828 per share in an open-market or private transaction. After this trade, he holds 26,291 Protagenic Therapeutics shares directly.

Insider Trade Summary

Net Buyer: 26,291 shares

Net Buy 1 txn

Insider ARMEN GARO H

Role EXEC. CHAIR & PRINCIPAL OFF.

Bought 26,291 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	COMMON STOCK	26,291	$0.1828	$5K

Holdings After Transaction: COMMON STOCK — 26,291 shares (Direct)

Key Figures

Shares purchased: 26,291 shares Purchase price: $0.1828 per share Direct holdings after trade: 26,291 shares +1 more

4 metrics

Shares purchased 26,291 shares Common stock bought by executive chair on July 30, 2026

Purchase price $0.1828 per share Price paid for PTIX common stock in reported transaction

Direct holdings after trade 26,291 shares Total common shares directly owned by Armen Garo after purchase

Net insider share change 26,291 shares Net buy shares reported across all transactions in this Form 4

Key Terms

open market or private transaction, direct ownership, Rule 10b5-1

3 terms

open market or private transaction financial

"Purchase in open market or private transaction"

direct ownership financial

"total_shares_following_transaction ... direct_or_indirect: "D""

Rule 10b5-1 financial

"The Form 4’s specific checkbox for Rule 10b5-1 plans was left unchecked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 05:29 PM Accepted by SEC EDGAR 08/03/2026 - 05:29 PM Learn about SEC filing dates

FAQ

What insider share purchase did PTIX report for Armen Garo?

Armen Garo, executive chair of Protagenic Therapeutics, bought 26,291 shares of common stock at $0.1828 per share on July 30, 2026, increasing his direct holdings to 26,291 shares according to a Form 4 submitted to the SEC.

At what price did the PTIX executive chair buy shares?

The executive chair purchased Protagenic Therapeutics common stock at $0.1828 per share. The transaction covered 26,291 shares in a purchase classified as an open-market or private transaction, as reflected in the Form 4 insider trading report.

How many PTIX shares does Armen Garo now directly own?

Following the reported transaction, Armen Garo directly owns 26,291 Protagenic Therapeutics shares. Before this purchase, his reported direct ownership position was lower, and this trade brought his total direct holdings to 26,291 shares of the company’s common stock.

Was the recent PTIX insider trade a purchase or a sale?

The recent insider trade by Protagenic Therapeutics executive chair Armen Garo was a purchase. He acquired 26,291 shares of common stock at $0.1828 per share, categorized as a purchase in an open-market or private transaction under SEC transaction code “P.”

Is the PTIX insider purchase reported under a Rule 10b5-1 plan?

The transaction is not reported as being made under a Rule 10b5-1 trading plan. The Form 4’s specific checkbox for Rule 10b5-1 plans was left unchecked, indicating the purchase was not designated as pursuant to such a pre-arranged plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARMEN GARO H

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protagenic Therapeutics, Inc.\new [ PTIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXEC. CHAIR & PRINCIPAL OFF.

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
COMMON STOCK	07/30/2026		P		26,291	A	$0.1828	26,291	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Garo H. Armen	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)